EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

SLC35A3 Remodels Site-Specific N-Glycosylation and Defines a Druggable Glycosylation Target in Hepatocellular Carcinoma

Qin Ouyang, Ke Gao, Xinwen Zhou, Jieyi Shi, Long Liao, Cun Wang, Shu Zhang

Molecular & Cellular Proteomics · 2026-11 · 25 (11) · 101672

DOI: 10.1016/j.mcpro.2026.101672 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular & Cellular Proteomics, 2026-11. Verfasst von Qin Ouyang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai…. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aberrant N-glycosylation contributes to hepatocellular carcinoma (HCC) progression, yet the upstream regulators that coordinate nucleotide-sugar transport and site-specific N-glycosylation remain poorly characterized. Here, we identified SLC35A3, a Golgi-resident UDP-GlcNAc transporter, as a glycosylation-related tumor suppressor in HCC. SLC35A3 was downregulated in HCC tissues, and its restoration suppressed cell proliferation and tumorigenicity. Mechanistically, SLC35A3 overexpression increased Golgi-resident UDP-GlcNAc levels, indicating enhanced substrate availability for glycosyltransferases. Intact N-glycopeptide profiling demonstrated that SLC35A3 overexpression reprogrammed site-specific N-glycan processing, characterized by a predominant reduction in high-mannose (HM) glycoforms and selective remodeling of fucosylated-sialylated (FS) glycoforms. Molecular docking identified poliumoside as a putative SLC35A3 binder with anti-tumor effect in HCC models. Together, our findings establish SLC35A3 as a critical node in Golgi-dependent N-glycan remodeling and highlight its potential as a target for pharmacological activation.

Schlagwörter

Stichwörter der Autor:innen

N-glycosylationSLC35A3UDP-GlcNAcglycoproteomicshepatocellular carcinoma

Autor:innen und Institutionen

  • Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, China.
  • Institutes of Biomedical Sciences, Fudan University, Shanghai, China.
  • State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute & Department of Liver Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, China. Electronic address: zhang.shu@zs-hospital.sh.cn.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Ouyang, Q., Gao, K., Zhou, X., Shi, J., Liao, L., Wang, C., & Zhang, S. (2026). SLC35A3 Remodels Site-Specific N-Glycosylation and Defines a Druggable Glycosylation Target in Hepatocellular Carcinoma. Molecular & Cellular Proteomics, 25(11), 101672. https://doi.org/10.1016/j.mcpro.2026.101672

Vancouver

Ouyang Q, Gao K, Zhou X, Shi J, Liao L, Wang C, et al. SLC35A3 Remodels Site-Specific N-Glycosylation and Defines a Druggable Glycosylation Target in Hepatocellular Carcinoma. Molecular & Cellular Proteomics. 2026;25(11):101672. doi:10.1016/j.mcpro.2026.101672

BibTeX
@article{Ouyang2026,
  author = {Ouyang, Qin and Gao, Ke and Zhou, Xinwen and Shi, Jieyi and Liao, Long and Wang, Cun and Zhang, Shu},
  title = {SLC35A3 Remodels Site-Specific N-Glycosylation and Defines a Druggable Glycosylation Target in Hepatocellular Carcinoma},
  journal = {Molecular & Cellular Proteomics},
  year = {2026},
  volume = {25},
  number = {11},
  pages = {101672},
  doi = {10.1016/j.mcpro.2026.101672}
}
Kostenlos starten →